1. Home
  2. AYTU vs CDIO Comparison

AYTU vs CDIO Comparison

Compare AYTU & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • CDIO
  • Stock Information
  • Founded
  • AYTU N/A
  • CDIO 2017
  • Country
  • AYTU United States
  • CDIO United States
  • Employees
  • AYTU N/A
  • CDIO N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • AYTU Health Care
  • CDIO Health Care
  • Exchange
  • AYTU Nasdaq
  • CDIO Nasdaq
  • Market Cap
  • AYTU 10.5M
  • CDIO 12.3M
  • IPO Year
  • AYTU N/A
  • CDIO N/A
  • Fundamental
  • Price
  • AYTU $1.72
  • CDIO $0.63
  • Analyst Decision
  • AYTU
  • CDIO Buy
  • Analyst Count
  • AYTU 0
  • CDIO 1
  • Target Price
  • AYTU N/A
  • CDIO $2.00
  • AVG Volume (30 Days)
  • AYTU 27.9K
  • CDIO 3.6M
  • Earning Date
  • AYTU 02-12-2025
  • CDIO 11-13-2024
  • Dividend Yield
  • AYTU N/A
  • CDIO N/A
  • EPS Growth
  • AYTU N/A
  • CDIO N/A
  • EPS
  • AYTU N/A
  • CDIO N/A
  • Revenue
  • AYTU $79,759,000.00
  • CDIO $35,688.00
  • Revenue This Year
  • AYTU N/A
  • CDIO $2,081.66
  • Revenue Next Year
  • AYTU N/A
  • CDIO $43.84
  • P/E Ratio
  • AYTU N/A
  • CDIO N/A
  • Revenue Growth
  • AYTU N/A
  • CDIO 180.90
  • 52 Week Low
  • AYTU $1.30
  • CDIO $0.19
  • 52 Week High
  • AYTU $3.45
  • CDIO $2.40
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 54.22
  • CDIO 44.77
  • Support Level
  • AYTU $1.68
  • CDIO $0.51
  • Resistance Level
  • AYTU $1.93
  • CDIO $0.62
  • Average True Range (ATR)
  • AYTU 0.12
  • CDIO 0.12
  • MACD
  • AYTU 0.00
  • CDIO -0.04
  • Stochastic Oscillator
  • AYTU 36.36
  • CDIO 26.52

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Share on Social Networks: